139 related articles for article (PubMed ID: 16250644)
1. Synthesis, structure-activity relationships, and biological properties of 1-heteroaryl-4-[omega-(1H-indol-3-yl)alkyl]piperazines, novel potential antipsychotics combining potent dopamine D2 receptor antagonism with potent serotonin reuptake inhibition.
Smid P; Coolen HK; Keizer HG; van Hes R; de Moes JP; den Hartog AP; Stork B; Plekkenpol RH; Niemann LC; Stroomer CN; Tulp MT; van Stuivenberg HH; McCreary AC; Hesselink MB; Herremans AH; Kruse CG
J Med Chem; 2005 Nov; 48(22):6855-69. PubMed ID: 16250644
[TBL] [Abstract][Full Text] [Related]
2. WS-50030 [7-{4-[3-(1H-inden-3-yl)propyl]piperazin-1-yl}-1,3-benzoxazol-2(3H)-one]: a novel dopamine D2 receptor partial agonist/serotonin reuptake inhibitor with preclinical antipsychotic-like and antidepressant-like activity.
Brennan JA; Graf R; Grauer SM; Navarra RL; Pulicicchio CM; Hughes ZA; Lin Q; Wantuch C; Rosenzweig-Lipson S; Pruthi F; Lai M; Smith D; Goutier W; van de Neut M; Robichaud AJ; Rotella D; Feenstra RW; Kruse C; Broqua P; Beyer CE; McCreary AC; Pausch MH; Marquis KL
J Pharmacol Exp Ther; 2010 Jan; 332(1):190-201. PubMed ID: 19828876
[TBL] [Abstract][Full Text] [Related]
3. SLV310, a novel, potential antipsychotic, combining potent dopamine D2 receptor antagonism with serotonin reuptake inhibition.
van Hes R; Smid P; Stroomer CN; Tipker K; Tulp MT; van der Heyden JA; McCreary AC; Hesselink MB; Kruse CG
Bioorg Med Chem Lett; 2003 Feb; 13(3):405-8. PubMed ID: 12565939
[TBL] [Abstract][Full Text] [Related]
4. Synthesis, potency, and in vivo evaluation of 2-piperazin-1-ylquinoline analogues as dual serotonin reuptake inhibitors and serotonin 5-HT1A receptor antagonists.
Zhou D; Stack GP; Lo J; Failli AA; Evrard DA; Harrison BL; Hatzenbuhler NT; Tran M; Croce S; Yi S; Golembieski J; Hornby GA; Lai M; Lin Q; Schechter LE; Smith DL; Shilling AD; Huselton C; Mitchell P; Beyer CE; Andree TH
J Med Chem; 2009 Aug; 52(15):4955-9. PubMed ID: 19719241
[TBL] [Abstract][Full Text] [Related]
5. 3,4-Dihydro-2H-benzoxazinones as dual-acting 5-HT1A receptor antagonists and serotonin reuptake inhibitors.
Lovell PJ; Blaney FE; Goodacre CJ; Scott CM; Smith PW; Starr KR; Thewlis KM; Vong AK; Ward SE; Watson JM
Bioorg Med Chem Lett; 2007 Feb; 17(4):1033-6. PubMed ID: 17129726
[TBL] [Abstract][Full Text] [Related]
6. Lu 35-138 ((+)-(S)-3-{1-[2-(1-acetyl-2,3-dihydro-1H-indol-3-yl)ethyl]-3,6-dihydro-2H-pyridin-4-yl}-6-chloro-1H-indole), a dopamine D4 receptor antagonist and serotonin reuptake inhibitor: characterisation of its in vitro profile and pre-clinical antipsychotic potential.
Hertel P; Didriksen M; Pouzet B; Brennum LT; Søby KK; Larsen AK; Christoffersen CT; Ramirez T; Marcus MM; Svensson TH; Di Matteo V; Esposito E; Bang-Andersen B; Arnt J
Eur J Pharmacol; 2007 Nov; 573(1-3):148-60. PubMed ID: 17689529
[TBL] [Abstract][Full Text] [Related]
7. Noncataleptogenic, centrally acting dopamine D-2 and serotonin 5-HT2 antagonists within a series of 3-substituted 1-(4-fluorophenyl)-1H-indoles.
Perregaard J; Arnt J; Bøgesø KP; Hyttel J; Sánchez C
J Med Chem; 1992 Mar; 35(6):1092-101. PubMed ID: 1348090
[TBL] [Abstract][Full Text] [Related]
8. SLV313 (1-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-4- [5-(4-fluoro-phenyl)-pyridin-3-ylmethyl]-piperazine monohydrochloride): a novel dopamine D2 receptor antagonist and 5-HT1A receptor agonist potential antipsychotic drug.
McCreary AC; Glennon JC; Ashby CR; Meltzer HY; Li Z; Reinders JH; Hesselink MB; Long SK; Herremans AH; van Stuivenberg H; Feenstra RW; Kruse CG
Neuropsychopharmacology; 2007 Jan; 32(1):78-94. PubMed ID: 16710314
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and structure-affinity relationship investigations of 5-heteroaryl-substituted analogues of the antipsychotic sertindole. A new class of highly selective alpha(1) adrenoceptor antagonists.
Balle T; Perregaard J; Ramirez MT; Larsen AK; Søby KK; Liljefors T; Andersen K
J Med Chem; 2003 Jan; 46(2):265-83. PubMed ID: 12519065
[TBL] [Abstract][Full Text] [Related]
10. Design and synthesis of novel arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.
Seo HJ; Park EJ; Kim MJ; Kang SY; Lee SH; Kim HJ; Lee KN; Jung ME; Lee M; Kim MS; Son EJ; Park WK; Kim J; Lee J
J Med Chem; 2011 Sep; 54(18):6305-18. PubMed ID: 21823597
[TBL] [Abstract][Full Text] [Related]
11. Indoline and piperazine containing derivatives as a novel class of mixed D(2)/D(4) receptor antagonists. Part 1: identification and structure-activity relationships.
Zhao H; Thurkauf A; He X; Hodgetts K; Zhang X; Rachwal S; Kover RX; Hutchison A; Peterson J; Kieltyka A; Brodbeck R; Primus R; Wasley JW
Bioorg Med Chem Lett; 2002 Nov; 12(21):3105-9. PubMed ID: 12372512
[TBL] [Abstract][Full Text] [Related]
12. Cyclic benzamides as mixed dopamine D2/serotonin 5-HT2 receptor antagonists: potential atypical antipsychotic agents.
Norman MH; Rigdon GC; Navas F; Cooper BR
J Med Chem; 1994 Aug; 37(16):2552-63. PubMed ID: 7914539
[TBL] [Abstract][Full Text] [Related]
13. Enhanced D1 affinity in a series of piperazine ring substituted 1-piperazino-3-arylindans with potential atypical antipsychotic activity.
Bøgesø KP; Arnt J; Frederiksen K; Hansen HO; Hyttel J; Pedersen H
J Med Chem; 1995 Oct; 38(22):4380-92. PubMed ID: 7473566
[TBL] [Abstract][Full Text] [Related]
14. Serotonin 5-HT2 receptor, dopamine D2 receptor, and alpha 1 adrenoceptor antagonists. Conformationally flexible analogues of the atypical antipsychotic sertindole.
Andersen K; Liljefors T; Hyttel J; Perregaard J
J Med Chem; 1996 Sep; 39(19):3723-38. PubMed ID: 8809161
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and activity of a new class of dual acting norepinephrine and serotonin reuptake inhibitors: 3-(1H-indol-1-yl)-3-arylpropan-1-amines.
Mahaney PE; Vu AT; McComas CC; Zhang P; Nogle LM; Watts WL; Sarkahian A; Leventhal L; Sullivan NR; Uveges AJ; Trybulski EJ
Bioorg Med Chem; 2006 Dec; 14(24):8455-66. PubMed ID: 16973367
[TBL] [Abstract][Full Text] [Related]
16. 5-HT reuptake inhibitors with 5-HT(1B/1D) antagonistic activity: a new approach toward efficient antidepressants.
Matzen L; van Amsterdam C; Rautenberg W; Greiner HE; Harting J; Seyfried CA; Böttcher H
J Med Chem; 2000 Mar; 43(6):1149-57. PubMed ID: 10737747
[TBL] [Abstract][Full Text] [Related]
17. New pyridobenzoxazepine derivatives derived from 5-(4-methylpiperazin-1-yl)-8-chloro-pyrido[2,3-b][1,5]benzoxazepine (JL13): chemical synthesis and pharmacological evaluation.
Liégeois JF; Deville M; Dilly S; Lamy C; Mangin F; Résimont M; Tarazi FI
J Med Chem; 2012 Feb; 55(4):1572-82. PubMed ID: 22268448
[TBL] [Abstract][Full Text] [Related]
18. Novel 5-HT6 receptor antagonists/D2 receptor partial agonists targeting behavioral and psychological symptoms of dementia.
Kołaczkowski M; Marcinkowska M; Bucki A; Śniecikowska J; Pawłowski M; Kazek G; Siwek A; Jastrzębska-Więsek M; Partyka A; Wasik A; Wesołowska A; Mierzejewski P; Bienkowski P
Eur J Med Chem; 2015 Mar; 92():221-35. PubMed ID: 25557493
[TBL] [Abstract][Full Text] [Related]
19. A study of the structure-affinity relationship in SYA16263; is a D
Onyameh EK; Bricker BA; Eyunni SVK; Voshavar C; Gonela UM; Ofori E; Jenkins A; Ablordeppey SY
Bioorg Med Chem; 2021 Jan; 30():115943. PubMed ID: 33338898
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and molecular modeling of new 1-aryl-3-[4-arylpiperazin-1-yl]-1-propane derivatives with high affinity at the serotonin transporter and at 5-HT(1A) receptors.
Orús L; Pérez-Silanes S; Oficialdegui AM; Martínez-Esparza J; Del Castillo JC; Mourelle M; Langer T; Guccione S; Donzella G; Krovat EM; Poptodorov K; Lasheras B; Ballaz S; Hervías I; Tordera R; Del Río J; Monge A
J Med Chem; 2002 Sep; 45(19):4128-39. PubMed ID: 12213056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
